1Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010 ;362 (12): 1090- 1101.
2Jayasena CN, Bloom SR. Role of gut hormones in obesity. Endocrinol Metab Clin North Am 2008 ;37 (3) : 769 - 787, xi.
3Wang Y, Guo XH. [Effects of GLP - I treatment on protec?tion of B cells in Otsuka Long - Evans Tokushima fatty rats] . Beijing Da Xue Xue Bao 2006 ;38 (4) : 375 - 380.
4Buse m, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26 - week random?ised , parallel - group, multinational, open -label trial (LEAD - 6) . Lancet 2009;374(9683): 39 -47.
5D'Alessio DA, Denney AM, Hermiller LM, et al. Treatment with the dipeptidyl peptidase - 4 inhibitor vildagliptin improves fasting islet - cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009;94(1): 81 -88.
6Vilsboll T, Brock B, Perrild H, et al. Liraglutide, a once - daily human GLP - I analogue, improves pancreatic B - cell function and arginine - stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008 ; 25 ( 2 ) : 152 -156.
7McClean PL, Gault VA, Irwin N, et al. Daily administration of the GIP - R antagonist (Pr03) GIP in streptozotocin - induced dia?betes suggests that insulin - dependent mechanisms are critical to anti - obesity - diabetes actions of (Pr03) GIP. Diabetes Obes Metab 2008;10(4): 336 -342.
8Wachters - Hagedoorn RE, Priebe MG, Heirnweg JA, et al. The rate of intestinal glucose absorption is correlated with plasma glu?cose - dependent insulinotropic polypeptide concentrations in healthy men. JNutr 2006;136(6): 1511-1516.
9vuseon T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 2004 ;47 (3) : 357 - 366.
